XNAS · BCAB
+3.62% · +$0.1300 · Vol 25.0K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
BioAtla, Inc. Common Stock

BioAtla, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$3.72
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is BCAB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for BCAB are being assembled.
About BioAtla, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
41
Country
US

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.70
Day high
$3.76
Day low
$3.50
Previous close
$3.59
52W high
$4.41
-15.65% from high
52W low
$3.44
29% of range
Market cap
$6M
EPS
$-5.0700
Shares out
1.7M
Volume
25K
VWAP
$3.62
Price history computed in-house
1W
-15.65%
1M
+8.14%
SMA 50 $3.75 · below
SMA 200 $3.75 · below
52W position 29%
Veridion warehouse edge

Warehouse intelligence for BCAB.

Veridion Score
78
0: 841: 392: 393: 904: 825: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

BCAB insider activity

BioAtla, Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for BCAB.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

BCAB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BCAB in this window.
Lobbying spend

BCAB lobbying filings, year to date.

Registered lobbying filings matched to BioAtla, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BCAB in this window.
Latest news · BCAB
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for BCAB.
Options
Sovereign unlock shows live options positioning for BCAB.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.